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Abstract This is a systematic review of eighty-two
published studies investigating the impact of DSM-IV
mental disorders on combination antiretroviral therapy
(cART) adherence and persistence among persons living
with HIV/AIDS (PLWHA). Sixty-two articles examined
depression, with 58 % (N = 32/62) finding lower cART
adherence and persistence. Seventeen articles examined
one or more anxiety disorders, with the majority finding no
association with cART adherence or persistence. Eighty
percent of the studies that evaluated the impact of psy-
chotic (N = 3), bipolar (N = 5) and personality disorders
(N = 2) on cART adherence and persistence also found no
association. Seven out of the nine studies (78 %) evaluat-
ing the impact of antidepressant treatment (ADT) on cART
adherence found improvement. Adherence and depression
measurements varied significantly in studies; common
research measurements would improve data harmonization.
More research specifically addressing the impact of other
mental disorders besides depression on cART adherence
and RCTs evaluating ADT on cART adherence are also
needed.
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Introduction
Combination antiretroviral therapy (cART) has greatly
improved the morbidity, and decreased the mortality
associated with HIV infection [1–3]. The benefits of cART,
however, are typically contingent upon excellent cART
adherence and persistence in order to achieve suppression
of HIV-1 RNA levels and an increase in CD4 T cell
lymphocytes [4, 5]. Suboptimal adherence to cART is
strongly related to viral proliferation [6, 7], drug resistance
[7, 8], disease progression [9], and death [3]. Factors that
can impair adherence to cART include drug addiction
[10–12], alcohol use disorders [11, 13], low socioeconomic
status [14], social stigma [15–17], neurocognitive disorders
[18], and mental disorders [19]. When combined, mental
disorders and substance use disorders among persons living
with HIV/AIDS (PLWHA) synergistically increase mor-
tality via impairing adherence to cART [20].
Mental disorders include a variety of psychiatric con-
ditions and are defined by the fourth Diagnostic Manual of
Mental Disorders (DSM-IV) [21] as ‘a clinically signifi-
cant behavioral or psychological impairment of an indi-
vidual’s normal cognitive, emotional, or behavioral
functioning associated with present distress and caused by
physiological or psychosocial factors’. Mental disorders
are more common among PLWHA (63 %) as compared to
the HIV-negative population (30.5 %) [19, 22]. In a
recently published study, HIV-positive men were more
likely to have any mood disorder [odds ratio (OR) = 6.10],
major depressive disorder/dysthymia (OR = 3.77), any
anxiety disorder (OR = 4.02), and any personality disorder
(OR = 2.50) when compared to their HIV-negative same-
sex counterparts [23]. In another study an estimated 60 %
of PLWHA receiving care in North Carolina had co-mor-
bid mental disorder symptoms [24].
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The mental disorder most commonly associated with
HIV infection is major depressive disorder (MDD) [25]
with a prevalence ranging from 16.2 % [26] to 36 % [25].
This is a four- to seven-fold greater prevalence than in the
general population (4.9 %) [27]. The large variation in
prevalence rates of mental disorders has been partially
attributed to differences in the specificity and sensitivity
of the study instruments used [28]. Mental disorders have
been associated with decreased adherence to cART and
impaired HIV virologic control in several studies [14, 29–
36]. In one longitudinal study, HIV-positive mothers with
co-morbid mental disorders were approximately six times
more likely to die than adherent participants with no
depressive symptoms [32]. A recently published meta-
analysis of 95 independent studies of PLWHA with
depressive disorders concluded that depression was sig-
nificantly associated with nonadherence to cART (r =
0.19; 95 % CI = 0.14–0.25, p \ 0.0001) [37]. This meta-
analysis, however, was not a systematic review of the
studies of depression and adherence to cART. To the
authors’ knowledge there has not yet been a systematic
review of studies published in the English literature
evaluating all major Axis I and II DSM-IV mental dis-
orders on cART adherence and persistence among adult
PLWHA.
The specific aim of this paper is to therefore systemat-
ically review studies evaluating the impact of all of major
Axis I and II DSM-IV mental disorders, excluding sub-
stance use disorders, on combination antiretroviral adher-
ence and persistence among PLWHA. Though major
depression is the principal focus of this review due to its
higher prevalence, other mental disorders such as anxiety
and psychotic disorders will also be examined as they have




PubMed, Scopus and Web of Knowledge were queried for
peer-reviewed original human research papers published in
English from 1996 to December 2011. Google Scholar was
also reviewed for details, full text, and additional articles.
The search for this systematic review took place from
November 2010 to December 2011. Keywords and their
combinations used in the search are available in an on-line
appendix. Papers were included if they were conducted in
other countries outside of the United States, given the high
prevalence of mental disorders among PLWHA throughout
the world.
Study Selection and Inclusion/Exclusion Criteria
Figure 1 represents a PRISMA (Preferred Reporting Items
for Systematic reviews and Meta-Analyses) flow diagram
for this systematic review [39]. The original search resulted
in 4,302 total documents (PubMed—2,151 articles, Sco-
pus—1,847 articles, Web of Knowledge—304 articles) of
which 2,676 articles remained after eliminating duplicate
articles. Of these, 659 articles met the following inclusion
criteria for the primary selection: [1] mental disorders,
including psychotic, mood, anxiety, somatoform, and per-
sonality disorders as defined by International Classification
of Diseases (ICD-9 and ICD-10) [40, 41], Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV Axis I or
II diagnosis) [21] or mental health symptoms (many studies
used screening tools for mental disorder symptoms, rather
than specific mental disorder diagnostic measures) [42]);
and [2] antiretroviral treatment adherence or persistence.
Articles included in this systematic review evaluated the
impact of DSM-IV mental disorders or mental health
symptoms on at least one of the following cART medica-
tion terms: (a) Adherence (synonym: compliance), defined
as ‘‘the extent to which a participant acts in accordance
with the prescribed interval, and dose of a dosing regimen’’
or ‘‘percentage of correctly timed doses (doses taken/doses
prescribed 9 100)’’ [43] and (b) persistence, defined as
‘‘the duration of time of initiation to discontinuation of
therapy (by the participant)’’ [43].
One reviewer (AD) identified the papers included in the
tables provided within this manuscript and in the electronic
appendix. A second independent reviewer (MA) applied
selection criteria to a random sample consisting of 20 % of
articles from the primary selection. Agreement between
reviewers was assessed using Cohen’s kappa (j) statistic
and was equal to 0.69 [44]. Where there were differences
between the two reviewers, a third reviewer (SAS) made
the final decision as to whether the article should be
included or excluded from the systematic review. Subse-
quently, 82 studies met the final inclusion criteria for this
systematic review.
Data Extraction
Standardized data collection forms were used to extract all
data including: study authors; study site; year and duration
of study; study design; population characteristics; sample
size; mental disorder studied and the tool used to screen
and diagnose the mental disorder; definition of and the tool
used to measure cART adherence. In cases where no
standardized tool was used for the mental disorder or cART
adherence, the tools used in the studies were noted in the
data collection form. The data collection form was similar
to Table 1 and the data was extracted at least twice from
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each article by one single author (AD). The study charac-
teristics in the tables were evaluated by one author (AD). If
inconsistencies in definitions of adherence or mental dis-
order were identified then further appraisal of the particular
issue would be carried out by two authors (AD and MZ)
and noted in the tables. For example, if it was identified
that the study did not use a standardized tool to create a
definition of depression, e.g. ‘depression defined as ever
being seen by a psychiatrist or taking ADT’, then the
problem with the particular definition would be written in
the extraction table, e.g. ‘definition of depression was
misleading because it may have included persons with a
past medical history of depression who are no longer
depressed introducing bias into results’.
In order to clearly present the results, the data were
separated into four categories according to the mental
disorder that was the main focus of the studies. Table 1
summarizes studies that evaluated ‘the impact of depres-
sive disorders on cART adherence and persistence’. These
constituted the majority of articles reviewed (62/82; 76 %).
Tables 2, 3 and 4 are presented as an electronic appendix.
Table 2 summarizes studies that examined the ‘impact of
specific mental disorders other than depression on cART
adherence and persistence’. Table 3 presents studies that
evaluated the ‘impact of mental disorders not specified per
DSM-IV diagnostic criteria on cART adherence and per-
sistence’. Finally, Table 4 summarizes articles that evalu-
ated ‘the impact of pharmacologic antidepressant treatment
(ADT) on cART adherence’ among PLWHA with
comorbid depressive disorders. Due to the length and scope
of the manuscript, behavioral treatments of depressive
disorders were not included in this systematic review. In
cases when cART persistence was measured instead of
cART adherence, the term used by the authors was noted in
the tables.
Results
This systematic review examines 82 studies evaluating the
impact of mental disorders and mental disorder symptoms
(including mood, anxiety, psychotic, and personality dis-
orders) on two primary outcomes: adherence to, and per-
sistence on cART (see Tables 1 in the manuscript and the
Tables 2, 3 and 4 within the electronic appendix).
Antiretroviral Adherence Measurements
Adherence to cART was assessed using multiple methods
(as highlighted in the Tables). Seventy-seven of the articles
used only one measurement of adherence, four studies used
two adherence measurements and one used three different
measures of cART adherence. These included: self-reports
(participants recall) (N = 65), electronic drug monitors
(EDMs) (N = 9), pharmacy refill record review (N = 6),
hospital or clinic record review (N = 2), unannounced pill
counts (N = 5), and directly observed therapy (DOT)
(N = 1), and some of the studies used a combination of the
aforementioned measures of adherence to cART (N = 5).
The time period over which adherence was assessed
ranged from 1 day to 1 year prior to the interview. Among
the self-report instruments, adherence recall periods ranged
Fig. 1 Systematic review study selection flow diagram
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I. Depressive disorders associated with decreased adherence to cART
Arnsten, J. H., X.
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(OR = 0.74, 95 %
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T: Previous 1 month
Depression—BDI–II MVA: Depression was
significantly associated
with non-adherence























T: Previous week or at
any visit before the
18th month of
treatment
Depression—CES–D MVA: Depression was
significantly related to
adherence failure
(OR = 2.5, 95 %
CI = 1.0–6.0,
p = 0.044)






970 participants M: Self-report (ACTG
questionnaire)
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adherence), Moderate
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and Poor (\80 %
adherence)
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236 participants M: UCSF Adherence
Questionnaire
D: Reasons for missing
medication






















D: [1] 100 % adherence
in the past 4 days, [2]
100 % adherence in the
past 1 month, and [3]
100 % refill in the past
3 months
T: Previous 4 days,
1 month and prior
consecutive 3 months















921 participants M: Self-report
D: Non-adherence: [1]
Missing 1 or more
doses; [2] missing 1 or
more appointments











adherence (OR = 0.57,
95 % CI = 0.39–0.84,
p \ 0.01)
Gonzalez, J. S.,
C. Psaros, et al.
(2011) USA
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MVA: Each unit increase
in the Clinical Global
Impression Scale was
associated with 75 %
increased odds of non-
adherence (OR = 1.75,
p = 0.002, 95 %
CI = 1.23–2.48). For
each SD MADRS













225 participants M: Self-report
D: Suboptimal
adherence: missing
[5 % of cART doses








twofold greater risk of
suboptimal adherence
at follow up
(RR = 1.8, 95 %
CI = 1.1–3.0)
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597 men M: Self-report
D: Dichotomized: 100 %
adherence or less than
100 % adherence
T: Previous 4 days
Depression—CES-D MVA: CES-D score[16
was an independent
predictor of decreasing
adherence (OR = 1.8,
p = 0.03)
Lazo, M., S.
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T : Previous 4 days










(OR = 1.44, 95 %
CI = 1.06–1.95,
p \ 0.05), but not
women





386 participants M: Self-report (of failing
to adhere to cART)
D: \100 % adherence







MVA: Depression was a
significant predictor of
poor adherence to
cART (OR = 0.69,
p = 0.03)






310 participants M: Self-report
D: Poor adherence:
\100 % adherence
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(v2 = 34.657, df = 1,
p \ 0.05)
















































their CES-D score was







(Coeff = 0.171, 95 %
CI = 0.087–0.283,
p \ 0.001)
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Depressive disorder and











720 participants M: Self-report (AACTG
questionnaire) and
VAS




adherence = 100 %
adherence on VAS






















T: Previous 4 days
Depression—BDI-II MVA: Participants at
risk of depression
(BDI [ 20) were more
likely to be non-
adherent (OR = 5.7,

















\100 % adherence (in
2005) or stopping
cART for 7 days or
more during the last
12 months (in 2008)
T: Previous 4 days
Depression—BDI-II MVA: Participants at
risk of moderate to
major depression
(BDI [ 20) were more
likely to be non-
adherent to cART in
the 4 days prior to
assessment in 2005,
and more likely to have
stopped cART for
7 days or more during
the last 12 months in
2008
Royal, S. W., D.











T: Previous 2 and 7 days
Depression—CES-D MVA: Depression was
associated with
decreased 2 day
(AOR = 1.73, 95 %
CI = 1.28–2.34,
p = 0.0003) and
7 days (AOR = 1.91,
95 % CI = 1.35–2.72,







310 participants M: Self-report (AACTG
questionnaire)
D: C90 % adherence
T: Previous 4 days
Depression-BDI II MVA: Severe depression
(AOR = 4.48, 95 %
CI = 1.64–12.27,
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the time)






adherence (OR = 0.34,
95 % CI = 0.18–0.64,
p \ 0.001)
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\80 % of medication
T: Previous 1 month
Depression—BDI and
POMS
MVA: POMS [ 42 was
significantly associated
with non-compliance
(OR = 1.4, 95 %
CI = 1.1–1.8,
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D: C95 % adherence
T: Previous 1, 3 and
7 days
Depression—BDI (cut-







(AOR = 2.8, 95 %
CI = 1.5–5.4,
p = 0.002)








M: Self-report to 3
adherence questions
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T: Previous week
Major depression—
CIDI-SF of the WHO
MVA: Participants with
depression were more
likely to be non-
adherent than those
without a MI.


























































D: 100 % adherence
T: Previous day
Depression- BDI MVA: Depression was
significantly related to
decreasing adherence
(OR = 0.924, 95 %
CI = 0.863–0.989,
p = 0.023)
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293 participants M: Self-report
D: C 95 % adherence
T: Previous 3 days




Catz, S. L., J.
A. Kelly, et al.
(2000) USA
Cross-sectional
study (Dec 1997 –
Aug 1998)
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72 participants M: Self-report
D: C95 % adherence
T: Previous 24 h, 4 days
and 7 days
Depression- BDI (cut-
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95 %
CI = 0.052–2.64,
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not included in the
analysis
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T: Previous 4 days





del Amo, et al.
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Cross-sectional
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179 participants M: Unannounced pill
counts
D: Non-adherent: taking
\85 % of medications
T: For 8 consecutive
months









38 participants M: Self-report (AACTG
questionnaire)
D: Adherent: no missed
doses
T: Previous 4 days
Depression—CES-D MVA: Depression was
not significantly
associated with cART








study, Mar 2004 -
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528 participants M: Self-report
D: Non-adherence:
missing at least one
dose of medications
T: Previous 3 days
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D: Non-adherence:
missing at least one
dose of medications





Mellins, C. A., J.




542 participants M: Self-report (AACTG
questionnaire)
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T: Previous 3 days



















‘‘In the last 7 days did
you feel: [1] that you
could not shake the
blues? [2] depressed?
[3] fearful? and [4] that
your sleep had been
restless?’’
MVA: Depression was
not found to be
significantly associated
with non-adherence
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T: Previous 30 days
MDD–BDI BVA: Current or past
diagnosis of MDD was
not associated non-
adherence (p [ 0.05)
Moss, A. R., J.
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182 participants M: Self-report and
medical records
D: Non-adherence: self-
report or presence of
non-adherence
behavior in the medical
records
T: Previous 3 months
Depression—HADS MVA: Depression was
not shown to be
associated with non-
adherence
Wagner, G. J., L.
M. Bogart, et al.
(2011) USA
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Springer, S. A., S.
Chen, et al.
(2009) USA
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Depression—CES-D,
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IV. Depressive disorder associated with decreased persistence on cART
Carrico, A. W., E.
D. Riley, et al.
(2011) USA
Cohort study (using
data from a RCT)












up assessments; and [3]
intermittent cART
utilization-stopping
and restarting cART at
least once
T: 25 months of follow-
up
Depression—BDI-I MVA: Depression at
baseline independently
predicted a 39 %
increase in the odds of
cART discontinuation



















least once; and [3]
Discontinued cART—
stopping all ART
between and still off
cART at end of
assessment period
T: Previous 6 months
(time between Vi and
Vi?1)




(OR = 1.97, 95 %
CI = 1.38–2.80), and
Discontinuing cART,
(OR = 2.03, 95 %
CI = 1.24–3.32) but
not for continuing
cART
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from: 1 day to 4 weeks; 7 days (the most commonly used
recall period) (N = 22 studies); 4 weeks (N = 12 studies);
4 days (N = 12 studies); 3 days (N = 10 studies); 2 days
(N = 6 studies); 3 months (N = 4 studies); 1 day (N = 4
studies); 2 weeks (N = 3 studies), and 5 days (N = 1
study). Adherence was reported either as a continuous or
binary (dichotomous) measure, either in association with
mental disorders or as the proportion of the sample meeting
a specified level of adherence. There was considerable
variation for binary (dichotomous) adherence measure and
its cut-off, differentially defined by studies as C75 %
adherence, C80 % adherence, C90 % adherence, C95 %
adherence, 100 % adherence, no missed doses, or a specific
number of missed doses for a given period of time.
Antiretroviral Persistence Measurements
Among five studies that measured cART regimen persis-
tence, four used self-report measures and one used EDMs,
self-report, and DOT combined. The time period over
which persistence was assessed ranged from 6 months to
3 years.
Measures of Mental Disorders
In addition to ICD-9, ICD-10 and DSM-IV diagnostic
criteria, other validated and non-validated screening tools
(see Table 1 in the manuscript and Tables 2 and 3 in the
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Maru, D. S., R.
D. Bruce, et al.
(2008) USA
6-month RCT of 2:1
to DAART versus
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T: Previous 6 months
Depression—CES-D BVA: The presence of




(HR = 2.4, 95 %
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statistic = 4.4;
p \ 0.05)
V. Depressive disorder associated with increased persistence on cART
Himelhoch, S., C.
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AACTG Adult AIDS Clinical Trials Group, ADT Anti-Depressant Therapy, AOR Adjusted Odds Ratio, BDI (-II) Beck Depression Index
(2nd Edition), BSI Brief Symptom Inventory, BVA Bivariate Analysis, CES-D Center for Epidemiologic Studies-Depression Scale, CIDI-SF
Composite International Diagnostic Interview-Short Form, DAART Directly Administered Antiretroviral Therapy, GDS Geriatric Depression
Scale, cART combination Antiretroviral Therapy, HADS Hospital Anxiety and Depression Scale, HSCL Hopkins Symptom Checklist-15, HR
Hazard Ratio, ICD-9-CM International Classification of Diseases, 9th Revision, Clinical Modification, IDU Injection Drug User, IES Impact of
Event Scale, IRR Incidence Rate Ratio, MADRAS Montgomery-Asberg Depression Rating Scale, EDMs Electronic Drug Monitors, MDD Major
Depressive Disorder, MSM Men who have sex with men, MINI Mini International Neuropsychiatric Interview, MVA Multivariate analysis, OR
Odds Ratio, PLWHA People Living with HIV/AIDS, POMS Profile of Mood States depression factor scale, PHQ-9 9- item Patient Health
Questionnaire, RCT Randomized Control Trials, RH Risk Hazard ratio, RR Relative Risk, SAT Self-administered therapy, SCAN Schedule for
Clinical Assessment in Neuropsychiatry, SCID-IV Structured Clinical Interview for DSM-IV, SD Standard Deviation, VAS Visual Analog Scale
a Participants: People Living with HIV/AIDS (PLWHA) [18 years old
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specific mental disorders and evaluate mental disorder
symptoms. The most commonly evaluated mental disorder
was depressive disorder (N = 62), followed by anxiety
disorders (N = 17), bipolar disorder (N = 5), psychotic
disorders (N = 3), personality disorders (N = 2), and
adjustment disorder (N = 2). Some studies evaluated more
than one mental disorder and used more than one instru-
ment to evaluate the presence of one or more mental dis-
orders. Depressive disorder and depressive symptoms were
measured by using one or two self-report scales in 60
studies whereas two studies used a diagnosis of depression
(ICD-9 code) on participants’ medical charts. The most
common instrument employed to assess depression and
depressive symptoms was the Center for Epidemiological
Studies Depression Scale (CES-D) [45, 46], (N = 23;
37 %) followed by the Beck Depression Inventory (BDI
and BDI-II) [47–50] (N = 18; 29 %) and the Structured
Clinical Interview for DSM-IV (SCID) [51] (four studies;
6 %), with the remaining studies using seventeen other
scales: Montgomery–Asberg Depression Rating Scale
(N = 3) [52], Brief Symptom Inventory (BSI) (N = 3)
[53], Hospital Anxiety and Depression Scale (HADS)
(N = 2), Composite International Diagnostic Interview-
Short Form (CIDI-SF), Mini International Neuropsychiat-
ric Interview (MINI) (N = 2), ICD-9 (N = 2), Hopkins
Symptom Checklist-15, Burnam’s interviewer adminis-
tered 8-item screening tool, Schedule for Clinical Assess-
ment in Neuropsychiatry (SCAN), Profile of Mood States
(POMS) depression factor scale, Brief (self-report)
screening measures of depression (PC-SAD) [54], Geriatric
Depression Scale (GDS) [55], Patient Health Questionnaire
(PHQ-9) (N = 2) [56], the 8-item depression scale from
the Medical Outcomes Study, the 15-item screening test
developed and used previously in Thailand (Thai Depart-
ment of Mental Health, 2006), and unspecified instruments
constructed from 3 to 4 questions (N = 2 studies) [57, 58].
Primary Outcomes Analysis
Two outcomes were evaluated in this systematic review:
(a) cART adherence and (b) cART persistence. Adherence
and persistence data for each article were extracted and are
presented in Tables 1 in the manuscript; and Tables 2, 3,
and 4 in the electronic appendix. The following sections
are grouped based on each mental disorder and the effect
on these two outcomes.
Adherence to cART
Impact of Depressive Disorders on cART Adher-
ence Fifty-eight studies evaluated the impact of depres-
sive disorder (as either the dependent or independent
variable) on cART adherence. These data are presented in
Table 1.
Depressive Disorders Associated with Decreased
Adherence to cART. Depressive disorders were signifi-
cantly associated with decreased cART adherence in thirty
out of 52 studies (57 %). Among these thirty studies,
thirteen were cohort [59–71], one was a randomized con-
trol trial (RCT) [72], and 16 were cross-sectional studies
[29, 57, 73–86]. The majority of these studies used self-
report measures for assessing the cART adherence variable
(N = 25/30, 83 %), while the other five studies used
EDMS, pharmacy refill data and unannounced pill counts
to assess adherence. Depression symptom measures were
used in the majority of these studies to assess the variable
‘depression’, with the CES-D (N = 13) and the BDI
(N = 7) as the most common measures. Twenty-seven of
the thirty studies (90 %) used multivariate analysis to
evaluate the association with depressive symptoms/diag-
nosis and poor cART adherence.
Depressive Disorders not Significantly Associated with
Adherence to cART. Twenty-two studies did not find a
statistically significant association between depression and
decreased cART adherence. Sixteen were cross-sectional
[34–36, 58, 87–98], whereas six were cohort studies
[38, 99–103]. The majority of these studies utilized a
diagnosis of depressive disorder at baseline (either via the
SCID, MINI, CIDI, HADS, or ICD-9 code) as the
depression variable (N = 10), while seven studies used a
depressive symptom scale, and the remainder of the studies
utilized other non-standardized measures to determine
depressive symptoms/disorder, such as the HSCL and a
non-specified scale. Multivariate analyses were reported
for finding an association with depressive disorder or
depressive symptoms and cART adherence in the majority
of these studies. The majority of studies utilized self-report
measures for the adherence variable.
Adherence Variable Predicts Depressive Symptoms. In
six studies, depression was the dependent variable while
adherence to cART was the independent variable [104–
109]. Five of these studies reported an association with
non-adherence to cART and higher depressive symptoms
[104–108]. The one study that did not find a statistically
significant association between cART adherence and
depression had a relatively smaller sample size (N = 84) as
compared to the studies that did find an association, was
completed earlier than the other studies (year 1997), and
only used a six-point likert scale to measure adherence
[109].
Impact of Anxiety Disorders on cART Adherence Table 2
lists seventeen articles that evaluated the impact of one or
more anxiety disorders on cART adherence. Anxiety dis-
orders included: (i) unspecified anxiety disorder (N = 8),
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(ii) generalized anxiety disorder (GAD, N = 3), (iii)
posttraumatic stress disorder (PTSD, N = 9), (iv) panic
disorder (N = 3), (v) agoraphobia (N = 1), or a combi-
nation of the above (see Table 2 in the electronic
appendix).
Impact of PTSD on cART Adherence. The relationship
between PTSD and cART adherence was examined by nine
studies (four cohort, and five cross-sectional studies). Two
studies (one prospective cohort and one cross-sectional)
found that PTSD was significantly associated with
decreased cART adherence [33, 34]. Both of these studies
utilized self-report adherence measures and examined
results with multivariate analyses. One of these studies
used the Post-Traumatic Diagnostic Scale (PDS) and the
Impact of Event Scale (IES) while the other study used the
IES only.
In one study, PTSD participants were significantly more
likely to adhere to cART than depressed participants. In
this study, 69 participants diagnosed with PTSD or
depression were classified into four groups according to the
severity of symptoms: (i) control (low PTSD/low depres-
sion); N = 22; (ii) PTSD (high PTSD/low depression),
N = 11; (iii) depressed (low PTSD/high depression),
N = 12); and (iv) mixed (high PTSD/high depression),
N = 24). The PTSD group was significantly more likely to
adhere to cART regimens compared to the depressed
group during the previous week (OR = 23.9, 95 % CI =
1.607–356.075) and during the previous 2 weeks of the
study (OR = 27.55; 95 % CI = 1.99–381.82) [110].
Six studies (three cross-sectional, two cohort and one
RCT) found no significant association between PTSD and
cART adherence [36, 59, 72, 94, 103, 111]. Adherence was
measured using self-report instruments in five studies and
EDM in one study. PTSD was measured using the SCID
(N = 2), PDS (N = 2), IES (N = 1) and a short form of
the widely used Davidson Trauma Scale (SPAN, N = 1).
Impact of Panic Disorder on cART Adherence. Three
studies examined the effect of panic disorder on cART
adherence. A study of 1,910 participants found that par-
ticipants with panic disorder were more likely to be non-
adherent to cART than those who were not diagnosed with
a mental disorder after being screened with the full CIDI
[68]. In the remaining two cross-sectional studies, panic
disorder diagnosed using the SCID-I was not significantly
associated with cART adherence [36, 94]. These two
studies used self-report instruments to measure adherence
to cART.
Impact of Generalized Anxiety Disorder (GAD) on cART
Adherence. The impact of GAD on cART adherence was
assessed in three reviewed articles.
One study reported that participants with GAD were
more likely to be non-adherent than those without a mental
disorder [68]. This cohort study of persons with a diagnosis
of GAD measured adherence by the ACTG 7-day recall
method, while the other two articles that found no signif-
icant association between GAD and cART adherence were
cross-sectional evaluations and used the ACTG 3-day
recall method [36, 94]. In one of these studies the partici-
pants had to have associated panic disorder in addition to
the GAD, therefore making the specific association with
GAD difficult to assess.
Impact of Other Anxiety Disorders (Agoraphobia,
Unspecified Anxiety Disorder) on cART Adherence. Ago-
raphobia was evaluated as a separate disorder in one cross-
sectional study of 542 participants, and was not found to be
significantly associated with cART adherence [36]. This
study used a self-report instrument to measure adherence to
cART and agoraphobia was diagnosed using the SCID.
Eight studies examined the association between an
unspecified anxiety disorder (defined as either anxiety
symptoms or anxiety disorders in general) and cART
adherence. In three articles, anxiety symptoms were sig-
nificantly associated with decreased cART adherence [10,
38, 111]. In these three studies, adherence was measured
using self-report instruments (N = 2) and pharmacy refill
(N = 1). Anxiety symptoms were measured using the
Hospital Anxiety and Depression Scale (HADS, N = 1),
State-Trait Anxiety Inventory (STAI, N = 1), and BSI
(N = 1). One of these studies reported the result based on
multivariate analysis and two of them reported the
results based on bivariate analysis. Four studies found no
statistically significant association between anxiety and
non-adherence [60, 83, 96, 109]. In these four studies,
adherence was measured using self-report instruments.
Anxiety symptoms were measured using Hospital Anxiety
and Depression Scale (HADS, N = 1), State-Trait Anxiety
Inventory (STAI, N = 1), Symptom Check List-90-
Revised (N = 1), and a self-administered questionnaire/
face-to-face interview of somatic symptoms of anxiety
(N = 1). Three of these studies reported the result based on
multivariate analysis whereas only one of them reported
the results based on bivariate analysis. In another study of
unspecified anxiety disorder, anxiety symptoms signifi-
cantly predicted that participants adhered to cART [91]. In
this cross-sectional study of 120 participants with non-
specific anxiety symptoms measured with the CIDI-SF
scale, cART adherence was measured using four dichoto-
mous non-adherent questions based on electronic medical
records.
Impact of Psychotic Disorder (Schizophrenia) on cART
Adherence Two cross-sectional studies did not find a
statistically significant association between schizophrenia/
psychotic disorder and cART adherence [94, 112]. In one
of these studies the presence of a psychotic disorder among
mentally ill participants was confirmed by a referring
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mental health professional, while in the other study the
presence of psychotic disorder among triply diagnosed
participants with HIV, substance abuse and mental disor-
ders was confirmed using the SCID. Both studies used self-
report measures to evaluate adherence to cART, however
one study assessed this with the ACTG 3-Day recall and
the other used self report and EDMs.
Impact of Personality Disorders on cART Adher-
ence Two cross-sectional studies examined the associa-
tion between personality disorders (borderline and
antisocial) and cART adherence. Both of these studies
utilized the self-report ACTG 3-day recall adherence
measure, but they differed in the subject populations. One
study of HIV? persons enrolled in multi-site cohort study
found no statistically significant association between bor-
derline or antisocial personality disorders and adherence
[36]. The other study of 107 HIV? participants with co-
occurring substance use disorders enrolled in a methadone
program found that borderline personality disorder was
associated with non-adherence to cART, while antisocial
personality disorder was not [94].
Impact of Bipolar Disorder on cART Adherence The
effect of having bipolar disorder on cART adherence was
examined in four cross-sectional studies. One study
reported that bipolar disorder was significantly associated
with decreased adherence to cART [35] and utilized EDMs
as the adherence tool. In three studies, bipolar disorder was
not significantly associated with decreased adherence to
cART [36, 94, 112]. Adherence tools and subject popula-
tions differed between these three studies.
Impact of Somatization, Dissociation, Adjustment Disorder
and Unspecified Mental Disorders on cART Adher-
ence One study found that levels of somatization
uniquely predicted adherence problems in a multivariate
model [109]. Another study found that dissociation mod-
erated the effect of PTSD on adherence resulting in lower
odds of cART adherence (OR = 0 0.95, p \ 0.05). PTSD
symptoms were significantly associated with lower odds of
adherence in individuals reporting high levels of dissocia-
tion (OR = 0.86, p \ 0.05) but not in those reporting low
levels of dissociation (OR = 1.02, p [ 0.05) [34].
Two cross-sectional studies found no significant asso-
ciation between adjustment disorder and cART adherence
[36, 94]. Both of these studies utilized the ACTG 3 -day
recall for cART adherence assessment.
Six studies included in this systematic review assessed
the impact of unspecified mental disorders on adherence to
cART. In these papers, mental disorder was either used as a
general term or combined with more than one mental dis-
order into one variable (see Table 3 in the electronic
appendix). All six studies (four cross-sectional and two
cohort) reported a significant association between the
mental disorder and decreased adherence to cART [6, 113–
117]. Adherence was measured using self-report instru-
ments in five studies and EDMs in one study. Five different
instruments were used to measure the presence of a mental
disorder (see Table 3 in the electronic appendix).
Persistence on cART
Impact of Depressive Disorder on cART Persistence Three
studies, two longitudinal cohort and one RCT, found that
depression was associated with decreased cART persistence
[31, 118, 119]. Another study found less cART discontinu-
ation in the first year among those with depressive disorder,
but there was no association with cART persistence after the
first year [120].
Impact of Bipolar Disorder on cART Persistence One
cohort study concluded that HIV? Medicaid beneficiaries
with severe affective disorder (defined as having bipolar
disorder plus major depressive disorder identified by ICD-9
codes) were significantly less persistent in their use of
cART than those without serious mental illness [121].
Impact of Psychotic Disorder on cART Persistence In one
cohort study, psychotic disorder (schizophrenia) identified
by ICD-9 coding was not significantly associated with
persistence on cART [121].
Impact of Unspecified Mental Disorder on cART Persis-
tence One cohort study of 4,989 PLWHA found that
compared to participants with no mental disorders, the
hazard probability for discontinuing cART was signifi-
cantly lower in the first and second years of treatment
among those with a severe mental disorder (defined as
ICD-9 codes for schizophrenia, other psychoses and bipo-
lar disorder). Among participants with mental disorders,
those with six or more mental health visits per year were
significantly less likely to discontinue cART compared
with participants with no mental health visits [120].
Impact of Antidepressant Treatment on Adherence to cART
Nine studies (seven cohort studies, one RCT, and one
cross-sectional study) evaluated the impact of pharmaco-
logic ADT on adherence to cART among depressed
PLWHA (see Table 4 in the electronic appendix). Seven
studies reported that pharmacologic treatment for depres-
sion was significantly associated with increased cART
adherence [69, 122–127], while in one study ADT of
depression was associated with decreased cART adher-
ence. In this study, however, pharmacotherapy was NOT
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specifically evaluated. The authors defined treatment of
depression as: ‘seeing a psychiatrist, receiving a diagnosis
of depression, or being prescribed ADT’ [11]. Therefore,
the construct validity of this study is problematic since the
employed definition of psychiatric treatment did not dis-
tinguish the treatment of depression from a diagnosis of
depression.
A RCT reported that participants receiving directly
observed fluoxetine for the treatment of depressive symp-
toms had similar cART adherence compared to participants
in the referral arm [128]. This study, however, had high
degrees of continuation of cART at the end of the study in
both arms (73 vs 75 %), suggesting an overall high degree
of persistence on therapy.
Discussion
DSM-IV mental disorders, especially depressive disor-
ders, are extremely common among PLWHA and have
been associated with decreased adherence to cART and
increased mortality [29, 32, 57, 73]. The literature con-
cerning HIV and mental disorders is staggering, yet the
data has yet to be rigorously appraised. Although a meta-
analysis studying the effect of depression on cART
adherence was recently published [37], this is to our
knowledge the first systematic review to examine the
impact of all mental disorders, with the exception of sub-
stance use disorders, on cART adherence and persistence
among PLWHA.
The majority of papers included in this review studied
the impact of depression on cART adherence and persis-
tence. Thirty of the 52 studies (57 %) that studied adher-
ence as the dependent variable, five out of six studies
(83 %) that studied adherence as the independent variable,
and three out of the four studies (75 %) that examined
persistence reported that a depressive disorder was asso-
ciated with a decrease in cART adherence and persistence.
Among these studies, 90 % based their results on multi-
variate analysis compared to 60 % of the studies that did
not find an association between depression and cART
adherence and persistence. One study reported a decreased
probability of cART discontinuation among those with
depressive disorders in the first year but not in subsequent
years [120]. This study, however, did not measure adher-
ence in itself, but rather cART discontinuation (cART
persistence) and defined it broadly as ceasing cART or
dropping out of active care. The 23 studies that found no
significant association between depression and adherence
and persistence to cART also tended to have a smaller
sample size (mean sample size = 195) as compared to the
35 studies that found positive associations (mean sample
size = 477).
Some of the reasons for why the studies of depressive
disorders found differing associations with adherence to
cART were likely attributed to the differences in whether
they utilized specific depression screening measures/
symptom rating scales (CES-D, BSI, PHQ) or standard
diagnostic tools of depressive disorder (SCID, MINI, CIDI)
to define the variable of ‘’depressive disorder’’. Most of the
studies that did not report a significant association with
adherence utilized more standard diagnostic tools of
depressive disorder such as the SCID, MINI, and CIDI. It
would be important for future research evaluations of
depression in HIV adherence research to improve data
harmonization by utilizing the categorization of depression
instruments that Simoni et al. [42] described as follows: [1]
standardized diagnostic interviews, that are commonly
used to assess the categorical diagnosis of depression based
on DSM or ICD criteria, (including in this category CIDI,
MINI, SCID, HADS, BDI etc.) [2] depression screening
instruments, that provide empirically based cut-offs and are
useful as the basis for referrals to more comprehensive
evaluations or to estimate the prevalence of possible
depression (including in this category CES-D and HSCL
etc.), and [3] symptom-rating scales, that are useful for
monitoring change in depression symptoms over time
(including in this category BDI, CES-D, HSCL, MADRS
etc.) [42]. Although there is no gold-standard for evalua-
tion of depression, it has been recommended that
researchers need to make informed choices based on the
characteristics of the study population and the purpose of
the research [42]. It is clear from this review that such
rigorous evaluation of the study intentions needs to be
applied in order to improve data harmonization efforts in
the future.
Other causes of differences in results of the depression
studies were likely due to the heterogeneity of the diag-
nostic and/or screening tools used for assessing depression.
For instance the CES-D, identified as a standardized tool to
screen for depressive symptoms, was the most commonly
used instrument among the papers included in this review
and it has twenty items, but not all versions are DSM-IV
compatible (i.e., early versions do not include items that
map directly onto DSM symptoms) [42]. Perhaps some of
the variability in studies evaluating the effect of depression
on cART adherence may have been associated with the
different versions of the CES-D as well as the different cut-
offs used to assess severity of depressive symptoms. Uni-
form assessment of depression is essential in order to
improve efforts at data harmonization across studies of
PLWHA. Harmonization of data can increase the likeli-
hood of finding an association with a common outcome
variable such as depression and adherence to cART. Fur-
thermore, if the goal of the research study is to identify
individuals with a clinical diagnosis of major depressive
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disorder, investigators should consider following up indi-
viduals who screen positive for depressive symptoms with
a full diagnostic interview such as the SCID, MINI or
CIDI, all of which have been validated with PLWHA in
both developed and developing countries [42, 129].
Investigators should also be careful when using medical
records (ICD-9 or DSM-IV codes) to identify participants
as having a diagnosis of ‘depression’, as was done in a few
of the evaluated studies. This particular method may mis-
identify a previous diagnosis of depression in a possibly
successfully treated participant thereby affecting the anal-
ysis of the adherence outcome variable.
The majority of the studies (N = 17/20 articles) evalu-
ating the impact of ‘specific mental disorders other than
depression’ on cART adherence and persistence (see
Table 2 in the electronic appendix) assessed anxiety dis-
orders. Anxiety disorders were associated with decreased
adherence in seven of the studies [unspecified anxiety
disorder (N = 3), GAD (N = 1), PTSD (N = 2), panic
disorder (N = 1)]; but no association was detected in the
majority of the studies (N = 15)) [Unspecified anxiety
disorder (N = 4), GAD (N = 2), PTSD (N = 6), panic
disorder (N = 2), and agoraphobia (N = 1). Although two
studies [unspecified anxiety disorder (N = 1), PTSD
(N = 1)] reported data suggesting that anxiety disorders
were associated with increased adherence to cART, one
study was conducted with a control group of participants
with high levels of depression, rather than a typical control
group without any mental disorder [110]; and the second
study, concluded that ‘‘screening positive for any anxiety
disorder reduced the risk of failing to take medications as
directed’’ [89]. Although the gross sample size of these
studies seems sufficient, the number of affected partici-
pants for each specific anxiety disorder may in effect not
have been large enough to reach statistical significance.
Given the high lifetime prevalence of anxiety disorders
among PLWHA (7 %) [130], however, studies evaluating
individual anxiety disorders are not sufficient in number.
To obtain a better understanding of the impact of specific
mental disorders on cART adherence other than depres-
sion, future well-designed prospective cohort studies and
RCTs with larger sample sizes for each specific disorder
should be conducted to assess for causality.
All of the studies assessing the impact of ‘unspecified
mental disorders’ on cART adherence concluded that
mental disorders are associated with decreased adherence
to cART. Importantly though, all of these studies included
depression/depressive symptoms as the mental disorder
variable [6, 113–117]. The result of these studies could
therefore be attributed to the direct effect of the depressive
disorder on adherence to cART. Only one study, which
assessed cART persistence as the dependent variable,
concluded that a severe mental disorder was significantly
associated with lower probability for cART discontinuation
in the first and second years (suggesting increased cART
persistence), compared to participants with no mental dis-
orders [120]. An additional finding of this study was that
persons with a mental disorder and with six or more mental
health visits per year were significantly less likely to dis-
continue cART compared to those with no mental health
visits. It is therefore plausible that increased mental health
visits in this study contributed to improved cART persis-
tence by enhancing linkage to health care, including HIV-
associated health-care [120].
The treatment of depression with antidepressants was
found to be associated with improved adherence in seven
of the nine studies (78 %) examining this effect. One of
these studies had a very small sample size of only nine
participants on ADT, therefore rendering any conclusions
questionable [122]. Three of the four studies that found
improved adherence to cART among participants adherent
to ADT used pharmacy records to measure adherence [123,
125, 127]. The use of pharmacy records as the sole indi-
cator of adherence could confound the adherence outcome
as participants who obtain their antidepressant medications
directly from pharmacies are more likely to pick up their
cART medications, thus ‘‘hiding’’ the direct effect of ADT
on cART adherence (via the improvement of depressive
symptoms). Furthermore, adherence to one medication
may indicate a propensity towards adherence in general.
Therefore participants who are adherent to ADT may be
more likely to adhere to cART simply because they are
more adherent as a rule, and not because of improved
depressive symptoms. In one study that did not find an
association between ADT and cART adherence, starting
psychiatric treatment was broadly defined as receiving a
diagnosis of depression, seeing a psychiatrist or taking
ADT, therefore making the individual effects of pharma-
cological, and non-pharmacological psychiatric treatment
impossible to unfurl [11]. A recent RCT of 137 HIV?
homeless and marginally housed persons found no signif-
icant difference in cART adherence among those receiving
directly observed fluoxetine as compared to the those
referred to the community for psychiatric care [128]. This
study however had high levels of persistence to cART at
the end of study in both groups (73 vs 75 % NS), as well as
similar percentages of viral suppression in both groups
(specific data not reported). These results suggest that
perhaps persistence to cART may be more significant than
adherence for a durable cART regimen.
Issues regarding differences between the studies in
specific ADTs as well as appropriate individual dosing,
however, make interpretation of the impact of ADT on
cART adherence for depression difficult. Little evidence
from randomized controlled clinical trials is available to
guide the psychiatric treatment of PLWHA [131]. Some
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studies, however, have shown that depression can be
effectively treated in PLWHA [132–134], specifically
using selective serotonin reuptake inhibitors (SSRIs) [135,
136]. Despite some possible evidence based from this
review that ADT may improve adherence to cART among
PLWHA who have co-morbid depression, it is still unclear
at this time whether treating depressive disorders with
ADT improves adherence to cART. Although other ADT
besides SSRIs including citalopram [137] and tricyclic
antidepressants [136, 138], have been shown to be effective
in treating depression among PLWHA, SSRIs [136, 139]
are better tolerated in PLWHA and recommended as first-
line agents for depression [140]. In devising research
involving antidepressants for PLWHA, however, clinicians
should control for the stage of HIV illness, co-morbid ill-
nesses such as hepatitis B and C, the potential for drug
interactions with cART, type of ADT, maximal dosing and
participants’ preferences [133, 141–143].
This systematic review also identified a large hetero-
geneity of measurements and definitions of adherence to
cART in various studies likely contributing to the variation
in outcomes. Overall the majority of studies utilized some
form of self-report, while fewer utilized EDMS, pharmacy
refill reviews, and unannounced pill counts. There is no
universally accepted ‘gold’ standard for the measurement
of cART adherence [144]. Self-report adherence measures
and other indirect measures such as EDMs and pill counts
have been found to distinguish between clinically mean-
ingful patterns of medication-taking behavior [145, 146].
Self-report, however, tends to overestimate adherence by
10–20 % as compared to EDMs evaluations because self-
report is susceptible to recall bias, inaccurate memory and
potentially to social desirability bias [147–149]. Pharmacy
record review, on the other hand, has been show to mis-
classify participants as non-adherent to cART in up to
43 % of the time when disregarding leftover medication
[150]. The variations in measurements utilized to evaluate
adherence to cART in the reviewed studies, as well as the
definition of recall period, likely contributed to the great
variation of the primary outcome, cART adherence.
There are some limitations to this review. Although we
were very rigorous with inclusion criteria and exclusion
criteria, it is plausible that some relevant papers that should
have been included were missed. Additionally, the exclu-
sion of behavioral treatments for depression and other
mental disorders constitutes a limitation when discussing
the scope of mental disorder treatments. Behavioral treat-
ments have overall been found to be effective in the treat-
ment of mental disorders, but due to the length of the paper
and the large quantity of data to be processed in the scope of
pharmacological treatment alone, it was decided to not
include studies on behavioral treatments in this particular
review. The inclusion of studies from both developed and
developing countries also could have introduced bias into
our findings since confounding factors such as barriers and
facilitators of cART adherence may be specific to different
geographic areas [151–153]. In developing countries, food
insufficiency [154–156] and health system deficiencies
have been found to undermine treatment continuity and
adherence to cART [157], whereas religiosity has been
shown to be positively correlated with cART adherence
[158]. Conversely, examining data from different parts of
the world increases the generalizability of our findings and
emphasizes the widespread nature of both mental disorders
and HIV.
Despite the limitations of the review, this is the first
paper to exhaustively review studies evaluating the asso-
ciation between DSM-IV mental disorders (excluding
substance use disorders) and adherence and persistence to
cART among adult PLWHA. Most of the studies included
in this review studied the adherence variable at a time
period when cART was more complex, requiring multi-
dose regimens. Current preferred once-daily dosing regi-
mens, however, have been recently shown to improve
adherence [159–162]. In a time when cART complexity
has decreased while potency of regimens has increased,
persistence to cART may be a superior indicator of HIV
outcomes than cART adherence and a better variable to
evaluate [4, 159, 163, 164]. Recent studies have found data
suggesting that adequate cART adherence may not be the
key factor in viral suppression [165]. Future studies should
evaluate the impact of mental disorders and their treatment
on HIV outcomes other than adherence such as maximal
viral suppression (i.e. HIV VL \48 copies/mL), neuro-
cognitive deficits, as well as liver and renal dysfunction.
Conclusions
The majority of the studies included in this systematic
review identified a significant association between
depressive symptoms/disorder and cART nonadherence
and non-persistence. Data related to the impact of specific
mental disorders other than depression (anxiety disorders,
bipolar disorder, psychotic disorders and personality dis-
orders) on adherence to cART are insufficient and incon-
sistent. Future research should focus specifically on each of
these mental disorders and cART adherence. Additionally,
common measures should be used to assess cART adher-
ence as well as specific mental disorders to improve data
harmonization across studies. Furthermore, the majority of
existing data suggest that treatment of depression with
ADT may be associated with improved adherence to cART
among PLWHA. Future RCT-designed studies will need to
be conducted to best determine the association between
improvement of depressive symptomatology and cART
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adherence. Lastly, HIV outcomes other than adherence to
cART, such as maximal HIV viral load suppression and
neurocognitive deficits are important to evaluate now that
more potent combination antiretroviral regimens are
available.
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